The development of proteasome inhibitors as anticancer drugs.

By J. Adams. Cancer Cell, 2004

788 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Building ubiquitin chains: E2 enzymes at work (2009, background): “Such drugs might join the proteasome inhibitor Velcade (also known as Bortezomib”
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “Conversely, inhibitors of the proteosome-ubiquination proteolysis pathway such as bortezomi”
Targeting the ubiquitin system in cancer therapy (2009, background): “Bortezomib downregulates NF-κB signalling by blocking IκB degradation, which seems to be its prevalent mechanism of action in human tumour”
The role of the unfolded protein response in tumour development: friend or foe? (2004, neutral): “Proteasome inhibitors are being used to successfully treat patients with multiple myelom”
Autophagy as a target for anticancer therapy (2011, background): “Inhibitors of mTORC1 Specific chemical inhibitors of the proteasome have emerged as effective antitumor therapies”